Recently, it was shown that, compared to VEGF-targeting alone, blocking VEGF, Ang-2, and programmed cell death protein-1 (PD-1) dramatically increased the survival of syngenic orthotopic GBM mice models [42]. The gene discussed is ANGPT2; the disease is glioblastoma.